Role of calcium-sensing receptor in mineral ion metabolism and inherited disorders of calcium-sensing

Molecular Genetics and Metabolism

Volumn 89, Issue 3, 2006, Pages 189-202

  Chattopadhyay, Naibedya ^a   Brown, Edward M ^b  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bone; Calcimimetic; Calcium homeostasis; Kidney; Parathyroid

Indexed keywords

1 (3 METHOXYPHENYL) N (3 PHENYLPROPYL)ETHYLAMINE; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; ETACRYNIC ACID; LOOP DIURETIC AGENT; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; PHOSPHATE; THIAZIDE DIURETIC AGENT; VITAMIN D;

ALLOSTERISM; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CELL FUNCTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; ELECTROLYTE DISTURBANCE; EXTRACELLULAR CALCIUM; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; GENE MUTATION; GENETIC DISORDER; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; METABOLIC REGULATION; NAUSEA AND VOMITING; NEONATAL SEVERE HYPERPARATHYROIDISM; NONHUMAN; OSTEOPOROSIS; PARATHYROID CELL; PARATHYROID FUNCTION; PARATHYROID HORMONE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SECONDARY HYPERPARATHYROIDISM; STATISTICAL ANALYSIS; UREMIA;

ANIMALS; CALCIUM METABOLISM DISORDERS; HOMEOSTASIS; HUMANS; MINERALS; MUTATION; RECEPTORS, CALCIUM-SENSING;

EID: 33748966446     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.07.003     Document Type: Review

References (137)

1. Okabe M., and Graham A. The origin of the parathyroid gland. Proc. Natl. Acad. Sci. USA 101 (2004) 17716-17719
2. 2+ and other ions as extracellular (first) messengers. Physiol. Rev. 71 (1991) 371-411
3. Bringhurst F.R., Demay M.B., and Kronenberg H.M. Hormones and disorders of mineral metabolism. In: Wilson J.D., Foster D.W., and Kronenberg H.M. (Eds). Williams Textbook of Endocrinology (1998), W.B. Saunders, Philadelphia 1155-1209
4. Brown E.M. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J. Clin. Endocrinol. Metab. 56 (1983) 572-581
5. 2+-sensing receptor from bovine parathyroid. Nature 366 (1993) 575-580
6. Garrett J.E., Capuano V., Hammerland L.G., Hung B.C., Brown E.M., Hebert S.C., Nemeth EF E.M., and Fuller F. Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J. Biol. Chem. 270 (1995) 2919-12925
7. 2+-sensing receptor cDNA from human kidney. Biochem. Biophys. Res. Commun. 214 (1995) 524-529
8. Riccardi D., Park J., Lee W.-S., Gamba G., Brown E.M., and Hebert S.C. Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc. Natl. Acad. Sci. USA 92 (1995) 131-135
9. Butters Jr. R.R., Chattopadhyay N., Nielsen P., Smith C.P., Mithal A., Kifor O., Bai M., Quinn S., Goldsmith P., Hurwitz S., Krapcho K., Busby J., and Brown E.M. Cloning and characterization of a calcium-sensing receptor from the hypercalcemic New Zealand white rabbit reveals unaltered responsiveness to extracellular calcium. J. Bone Miner. Res. 12 (1997) 568-579
10. Garrett J.E., Tamir H., Kifor O., Simin R.T., Rogers K.V., Mithal A., Gagel R.F., and Brown E.M. Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology 136 (1995) 5202-5211
11. Ruat M., Molliver M.E., Snowman A.M., and Snyder S.H. Calcium sensing receptor: molecular cloning from rat striatal library and localization to nerve terminals. Proc. Natl. Acad. Sci. USA 92 (1995) 3161-3165
12. Brown E.M., and MacLeod R.J. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 81 (2001) 239-297
13. Felder C.B., Graul R.C., Lee A.Y., Merkle H.P., and Sadee W. The Venus flytrap of periplasmic binding proteins: an ancient protein module present in multiple drug receptors. AAPS Pharm. Sci. 1 (1999) E2
14. Oh B.-H., Pandit J., Kang C.-H., Nikaido K., Gokcen S., Ames G.F., and Kim S.H. Three-dimensional structures of the periplasmic lysine/arginine/ornithine-binding protein with and without a ligand. J. Biol. Chem. 268 (1993) 11348-11355
15. Bai M., Trivedi S., and Brown E.M. Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells. J. Biol. Chem. 273 (1998) 23605-23610
16. 2+ receptor. J. Biol. Chem. 274 (1999) 27642-27650
17. 2+-sensing receptor: implications for its structure and function. Trends Endocrinol. Metab. 14 (2003) 282-288
18. 2+ binding pocket within the venus flytrap module of the human calcium-sensing receptor. J. Biol. Chem. 280 (2005) 37917-37923
19. 2+-sensing receptor. Proc. Natl. Acad. Sci. USA 97 (2000) 4814-4819
20. Zhang Z., Jiang Y., Quinn S.J., Krapcho K., Nemeth E.F., and Bai M. l-Phenylalanine and NPS R-467 synergistically potentiate the function of the extracellular calcium-sensing receptor through distinct sites. J. Biol. Chem. 277 (2002) 33736-33741
21. 2+ receptor. J. Biol. Chem. 277 (2002) 18908-18913
22. 2+ store release. J. Biol. Chem. 273 (1998) 21267-21275
23. 2+-sensing receptor (CaR) activates phospholipases C, A2, and D in bovine parathyroid and CaR-transfected, human embryonic kidney (HEK293) cells. J. Bone Miner. Res. (1997) 715-725
24. Hjalm G., MacLeod R.J., Kifor O., Chattopadhyay N., and Brown E.M. Filamin-A binds to the carboxyl-terminal tail of the calcium-sensing receptor, an interaction that participates in CaR-mediated activation of mitogen-activated protein kinase. J. Biol. Chem. 276 (2001) 34880-34887
25. Awata H., Huang C., Handlogten M.E., and Miller R.T. Interaction of the calcium-sensing receptor and filamin, a potential scaffolding protein. J. Biol. Chem. 276 (2001) 34871-34879
26. Kifor O., Diaz R., Butters R., Kifor I., and Brown E.M. The calcium-sensing receptor is localized in caveolin-rich plasma membrane domains of bovine parathyroid cells. J. Biol. Chem. 273 (1998) 21708-21713
27. Zhang M., and Breitwieser G.E. High affinity interaction with filamin A protects against calcium-sensing receptor degradation. J. Biol. Chem. 280 (2005) 11140-11146
28. Pi M., Faber P., Ekema G., Jackson P.D., Ting A., Wang N., Fontilla-Poole M., Mays R.W., Brunden R.W.K.R., Harrington J.J., and Quarles L.D. Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J. Biol. Chem. 280 (2005) 40201-40209
29. 2+-sensing receptor. Trends Pharmacol. Sci. 21 (2000) 401-407
30. Quinn S.J., Kifor O., Trivedi S., Diaz R., Vassilev P., and Brown E. Sodium and ionic strength sensing by the calcium receptor. J. Biol. Chem. 273 (1998) 19579-19586
31. 2+-sensing receptor: a target for polyamines. Am. J. Physiol. 273 (1998) C1315-C1323
32. 2+-permeable channels through calcium-sensing receptors. J. Neurosci. Res. 47 (1997) 547-554
33. Miki H., Maercklein P.B., and Fitzpatrick L.A. Effect of magnesium on parathyroid cells: evidence for two sensing receptors or two intracellular pathways?. Am. J. Physiol. 272 (1997) E1-E6
34. 2+-sensing receptor is a promiscuous divalent cation sensor that responds to lead. Am. J. Physiol. Renal Physiol. 279 (2000) F1083-F1091
35. Brown E.M., Fuleihan G.E.-H., Chen C.J., and Kifor O. A comparison of the effects of divalent and trivalent cations on parathyroid hormone release, 3′,5′-cyclic-adenosine monophosphate accumulation, and the levels of inositol phosphates in bovine parathyroid cells. Endocrinology 127 (1990) 1064-1071
36. Marie P.J. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr. Opin. Rheumatol. 18 Suppl. 1 (2006) S11-S15
37. Coulombe J., Faure H., Robin B., and Ruat M. In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor. Biochem. Biophys. Res. Commun. 323 (2004) 1184-1190
38. Pi M., and Quarles L.D. A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. J. Bone Miner. Res. 19 (2004) 862-869
39. Nearing J., Betka M., Quinn S., Hentschel H., Elger M., Baum M., Bai M., Chattopadyhay N., Brown E.M., Hebert S.C., and Harris H.W. Polyvalent cation receptor proteins (CaRs) are salinity sensors in fish. Proc. Natl. Acad. Sci. USA 99 (2002) 9231-9236
40. Flanagan J.A., Bendell L.A., Guerreiro P.M., Clark M.S., Power D.M., Canario A.V., Brown B.L., and Ingleton P.M. Cloning of the cDNA for the putative calcium-sensing receptor and its tissue distribution in sea bream (Sparus aurata). Gen. Comp. Endocrinol. 127 (2002) 117-127
41. Quinn S.J., Bai M., and Brown E.M. pH Sensing by the calcium-sensing receptor. J. Biol. Chem. 279 (2004) 37241-37249
42. Nemeth E.F., Steffey M.E., Hammerland L.G., Hung B.C., Van Wagenen B.C., DelMar E.G., and Balandrin M.F. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. USA 95 (1998) 4040-4045
43. Hammerland L.G., Krapcho K.J., Garrett J.E., Alasti N., Hung B.C., Simin R.T., Levinthal C., Nemeth E.F., and Fuller F.H. NPS R-467 activation of chimeric calcium-metabotropic glutamate receptor and a calcium receptor deletion mutant indicates a site of action within the transmembrane domain of the calcium receptor. J. Bone Miner. Res. 11 Suppl. 1 (1996) S158 (Abstract P272)
44. Miedlich S.U., Gama L., Seuwen K., Wolf R.M., and Breitwieser G.E. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 279 (2004) 7254-7263
45. 2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J. Biol. Chem. 279 (2004) 18990-18997
46. Nemeth E.F. Pharmacological regulation of parathyroid hormone secretion. Curr. Pharm. Des. 8 (2002) 2077-2087
47. Gowen M., Stroup G.B., Dodds R.A., James I.E., Votta B.J., Smith B.R., Bhatnagar P.K., Lago A.M., Callahan J.F., DelMar E.G., Miller M.A., Nemeth E.F., and Fox J. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J. Clin. Invest. 105 (2000) 1595-1604
48. 2+-sensing receptor. Proc. Natl. Acad. Sci. USA 97 (2000) 4814-4819
49. Conigrave A.D., Mun H.C., Delbridge L., Quinn S.J., Wilkinson M., and Brown E.M. l-Amino acids regulate parathyroid hormone secretion. J. Biol. Chem. 279 (2004) 38151-38159
50. 2+-sensing receptor is required for l-amino acid sensing. J. Biol. Chem. 279 (2004) 51739-51744
51. 2+-sensing receptor's venus flytrap domain that selectively disables l-amino acid sensing. J. Biol. Chem. 280 (2005) 29067-29072
52. Freichel M., Zink-Lorenz A., Holloschi A., Hafner M., Flockerzi V., and Raue F. Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion. Endocrinology 137 (1996) 3842-3848
53. 2+-sensing receptor and PTH/PTHrP receptor in rat kidney. Am. J. Physiol. 271 (1996) F951-F966
54. 2+/polyvalent cation-sensing protein in rat kidney. Am. J. Physiol. 274 (1998) F611-F622
55. Chattopadhyay N., Baum M., Bai M., Riccardi D., Hebert S.C., Harris H.W., and Brown E.M. Ontogeny of the extracellular calcium-sensing receptor in rat kidney. Am. J. Physiol. 271 (1996) F736-F743
56. Sands J.M., Naruse M., Baum M., Jo I., Hebert S.C., Brown E.M., and Harris H.W. Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. J. Clin. Invest. 99 (1997) 1399-1405
57. Gillin A.G., Star R.A., and Sands J.M. Osmolarity-stimulated urea transport in rat terminal IMCD: role of intracellular calcium. Am. J. Physiol. 265 (1993) F272-F277
58. 2+ as an extracellular signal in bone. Cell Calcium 35 (2004) 249-255
59. 2+-sensing receptors in intestinal epithelium. Am. J. Physiol. 273 (1997) C1168-C1175
60. Chattopadhyay N., Cheng I., Rogers K., Riccardi D., Hall A., Diaz R., Hebert S.C., Soybel D.I., and Brown E.M. Identification and localization of extracellular Ca(2+)-sensing receptor in rat intestine. Am. J. Physiol. 274 (1998) G122-G130
61. Ba J., Brown D., and Friedman P.A. Calcium-sensing receptor regulation of PTH-inhibitable proximal tubule phosphate transport. Am. J. Physiol. Renal Physiol. 285 (2003) F1233-F1243
62. 2+-sensing receptor in divalent mineral ion homeostasis. J. Exp. Biol. 200 (1997) 295-302
63. Rogers K.V., Dunn C.K., Hebert S.C., and Brown E.M. Localization of calcium receptor mRNA in the adult rat central nervous system by in situ hybridization. Brain Res. 744 (1997) 47-56
64. Washburn D.L., Smith P.M., and Ferguson A.V. Control of neuronal excitability by an ion-sensing receptor (correction of anion-sensing). Eur. J. Neurosci. 11 (1999) 1947-1954
65. Hoenderop J.G., Nilius B., and Bindels R.J. Calcium absorption across epithelia. Physiol. Rev. 85 (2005) 373-422
66. 2+-induced relaxation. Am. J. Physiol. 276 (1999) H1035-H1042
67. Yamaguchi T. Cacium-sensing receptor in bone. In: Chattopadhyay N., and Brown E.M. (Eds). Calcium-sensing Receptor (2003), Kluwer Academic Publishers, Boston 103-115
68. Takahashi E., Mukohyama H., Aoki K., Duarte W.R., Lerner U.H., Ohya K., Omura K., and Kasugai S. High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture. J. Med. Dent. Sci. 49 (2002) 109-120
69. Kanatani M., Sugimoto T., Kanzawa M., Yano S., and Chihara K. High extracellular calcium inhibits osteoclast-like cell formation by directly acting on the calcium-sensing receptor existing in osteoclast precursor cells. Biochem. Biophys. Res. Commun. 261 (1999) 144-148
70. Kaji H., Sugimoto T., Kanatani M., and Chihara K. High extracellular calcium stimulates osteoclast-like cell formation and bone-resorbing activity in the presence of osteoblastic cells. J. Bone Miner. Res. 11 (1996) 912-920
71. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 757 (1993) 1297-1303
72. Brown E.M. Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Endocrinol. Metab. Clin. North Am. 29 (2000) 503-522
73. Foley Jr. T.P., Harrison H.C., Arnaud C.D., and Harrison H.E. Familial benign hypercalcemia. J. Pediatr 81 (1972) 1060-1067
74. Marx S.J., Fraser D., and Rapoport A. Familial hypocalciuric hypercalcemia. Mild expression of the gene in heterozygotes and severe expression in homozygotes. Am. J. Med. 78 (1985) 15-22
75. Marx S.J., Attie M.F., Levine M.A., Spiegel A.M., Downs Jr. R.W., and Lasker R.D. The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine (Baltimore) 60 (1981) 397-412
76. Chou Y.H., Brown E.M., Levi T., Crowe G., Atkinson A.B., Arnqvist H.J., Toss G., Fuleihan G.E., Seidman J.G., and Seidman C.E. The gene responsible for familial hypocalciuric hypercalcemia maps to chromosome 3q in four unrelated families. Nat. Genet. 1 (1992) 295-300
77. Heath III H., Jackson C.E., Otterud B., and Leppert M.F. Genetic linkage analysis in familial benign (hypocalciuric) hypercalcemia: evidence for locus heterogeneity. Am. J. Hum. Genet. 53 (1993) 193-200
78. Trump D., Whyte M.P., Wooding C., Pang J.T., Pearce S.H., Kocher D.B., and Thakker R.V. Linkage studies in a kindred from Oklahoma, with familial benign (hypocalciuric) hypercalcaemia (FBH) and developmental elevations in serum parathyroid hormone levels, indicate a third locus for FBH. Hum. Genet. 96 (1995) 183-187
79. Lloyd S.E., Pannett A.A., Dixon P.H., Whyte M.P., and Thakker R.V. Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13. Am. J. Hum. Genet. 64 (1999) 189-195
80. Auwerx J., Demedts M., and Bouillon R. Altered parathyroid set point to calcium in familial hypocalciuric hypercalcemia. Acta Endocrinol. 106 (1984) 215-218
81. Bai M., Janicic N., Trivedi S., Quinn S., Cole D., Brown E., and Hendy G. Markedly reduced activity of mutant calcium-sensing receptor with an inserted Alu element from a kindred with familial hypocalciuric hypercalcemia and neonatal severe hyperpara-thyroidism. J. Clin. Invest. 99 (1997) 1917-1925
82. 2+ -sensing receptor. J. Biol. Chem. 271 (1996) 19537-19545
83. 2+-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. J. Clin. Invest. 99 (1997) 88-96
84. Pearce S.H., Bai M., Quinn S., Kifor O., Brown E.M., and Thakker R.V. Functional characterization of calcium-sensing receptor mutations expressed in human embryonic kidney cells. J. Clin. Invest. 98 (1996) 1860-1866
85. Bai M., Trivedi S., Kifor O., Quinn S.J., and Brown E.M. Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function. Proc. Natl. Acad. Sci. USA 96 (1999) 2834-2839
86. Scillitani A., Guarnieri V., De Geronimo S., Muscarella L.A., Battista C., D'Agruma L., Bertoldo F., Florio C., Minisola S., Hendy G.N., and Cole D.E. Blood ionized calcium is associated with clustered polymorphisms in the carboxyl-terminal tail of the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 89 (2004) 5634-5638
87. Pasieka J., Andersen M., and Hanley D. Familial benign hypercalcemia: hypercalciuria and hypcalciuria in affected members of a small kindered. Clin. Endocrinol. 33 (1990) 429-433
88. Carling T., Szabo E., Bai M., Ridefelt P., Westin G., Gustavsson P., Trivedi S., Hellman P., Brown E.M., Dahl N., and Rastad J. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J. Clin. Endocrinol. Metab. 85 (2000) 2042-2047
89. Pratt E.L., Beren B.B., and Neuhauser E.B.D. Hypercalcemia and idiopathic hyperplasia of the parathyroid glands in an infant. J. Pediatr. 30 (1947) 388-399
90. Hillman D.A., Scriver C.R., Pedvis S., and Shragovitch I. Neonatal familial hyperparathyroidism. N. Engl. J. Med. 270 (1964) 483-490
91. Gaudelus J., Dandine M., Nathanson M., Perelman R., and Hassan M. Rib cage deformity in neonatal hyperparathyroidism. Am. J. Dis. Child. 137 (1983) 408-409
92. Heath H.D. Familial hypocalciuric hypercalcemia. In: Bilezekian J., Marcus R., and Levine M. (Eds). The Parathyroids (1994), Raven Press, New York 699-710
93. Pearce S.H., and Steinmann B. Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism. Clin. Endocrinol. (Oxf) 50 (1999) 691-693
94. Marx S.J., Lasker R.D., Brown E.M., Fitzpatrick L.A., Sweezey N.B., Goldbloom R.B., Gillis D.A., and Cole D.E. Secretory dysfunction in parathyroid cells from a neonate with severe primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 62 (1986) 445-449
95. Waller S., Kurzawinski T., Spitz L., Thakker R.V., Cranston T., Pearce S.H., Cheetham T., and van't Hoff W.G. Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. Eur. J. Pediatr. 163 (2004) 589-594
96. Zhang Z., Qiu W., Quinn S.J., Conigrave A.D., Brown E.M., and Bai M. Three adjacent serines in the extracellular domains of the CaR are required for l-amino acid-mediated potentiation of receptor function. J. Biol. Chem. 277 (2002) 33727-33735
97. Pollak M.R., Chou Y.-H., Marx S.J., Steinmann B., Cole D.E., Brandi M., Papapoulos S., Menko F., Hendy G.E., Brown E.M., Seidman C.E., and Seidman J.G. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J. Clin. Invest. 93 (1994) 1108-1112
98. Pollak M.R., Brown E.M., Estep H.L., McLaine P.N., Kifor O., Park J., Hebert S.C., Seidman C.E., and Seidman J.G. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat. Genet. 8 (1994) 303-307
99. Lienhardt A., Garabedian M., Bai M., Sinding C., Zhang Z., Lagarde J.P., Boulesteix J., Rigaud M., Brown E.M., and Kottler M.L. A large homozygous or heterozygous in-frame deletion within the calcium-sensing receptor's carboxylterminal cytoplasmic tail that causes autosomal dominant hypocalcemia. J. Clin. Endocrinol. Metab. 85 (2000) 1695-1702
100. Watanabe S., Fukumoto S., Chang H., Takeuchi Y., Hasegawa Y., Okazaki R., Chikatsu N., and Fujita T. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 360 (2002) 692-694
101. Vargas-Poussou R., Huang C., Hulin P., Houillier P., Jeunemaitre X., Paillard M., Planelles G., Dechaux M., and Miller R.T. Antignac C Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J. Am. Soc. Nephrol. 13 (2002) 2259-2266
102. Hebert S.C. Bartter syndrome. Curr. Opin. Nephrol. Hypertens. 12 (2003) 527-532
103. 2+ receptor. FEBS Lett. 448 (1999) 180-184
104. 2+-sensing receptor. J. Clin. Endocrinol. Metab. 82 (1997) 2710-2715
105. Blizzard R.M., Chee D., and Davis W. The incidence of adrenal and other antibodies in the sera of patients with idiopathic adrenal insufficiency (Addison's disease). Clin. Exp. Immunol. 2 (1967) 19-30
106. Posillico J.T., Wortsman J., Srikanta S., Eisenbarth G.S., Mallette L.E., and Brown E.M. Parathyroid cell surface autoantibodies that inhibit parathyroid hormone secretion from dispersed human parathyroid cells. J. Bone Miner. Res. 1 (1986) 475-483
107. Li Y., Song Y.H., Rais N., Connor E., Schatz D., Muir A., and Maclaren N. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. Clin. Invest. 97 (1996) 910-914
108. Kifor O., McElduff A., LeBoff M.S., Moore Jr. F.D., Butters R., Gao P., Cantor T.L., Kifor I., and Brown E.M. Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J. Clin. Endocrinol. Metab. 89 (2004) 548-556
109. Kifor O., Moore Jr. F.D., Delaney M., Garber J., Hendy G.N., Butters R., Gao P., Cantor T.L., Kifor I., Brown E.M., and Wysolmerski J. A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 88 (2003) 60-72
110. Ho C., Conner D.A., Pollak M.R., Ladd D.J., Kifor O., Warren H.B., Brown E.M., Seidman J.G., and Seidman C.E. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat. Genet. 11 (1995) 389-394
111. Kos C.H., Karaplis A.C., Peng J.B., Hediger M.A., Goltzman D., Mohammad K.S., Guise T.A., and Pollak M.R. The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J. Clin. Invest. 111 (2003) 1021-1028
112. Tu Q., Pi M., Karsenty G., Simpson L., Liu S., and Quarles L.D. Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J. Clin. Invest. 111 (2003) 1029-1037
113. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81 (1996) 1598-1606
114. Gogusev J., Duchambon P., Hory B., Giovannini M., Goureau Y., Sarfati E., and Drueke T.B. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 51 (1997) 328-336
115. Mathias R.S., Nguyen H.T., Zhang M.Y., and Portale A.A. Reduced expression of the renal calcium-sensing receptor in rats with experimental chronic renal insufficiency. J. Am. Soc. Nephrol. 9 (1998) 2067-2074
116. Ritter C.S., Finch J.L., Slatopolsky E.A., and Brown A.J. Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int. 60 (2001) 1737-1744
117. Rodriguez M., Nemeth E.F., and Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am. J. Physiol. Renal Physiol. 288 (2005) F253-F264
118. Brown A.J., Zhong M., Finch J., Ritter C., McCracken R., Morrissey J., and Slatopolsky E. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am. J. Physiol. 270 (1996) F454-F460
119. 2+ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther. 299 (2001) 323-331
120. Silverberg S.J., Bone III H.G., Marriott T.B., Locker F.G., Thys-Jacobs S., Dziem G., Kaatz S., Sanguinetti E.L., and Bilezikian J.P. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N. Engl. J. Med. 337 (1997) 1506-1510
121. Shoback D.M., Bilezikian J.P., Turner S.A., McCary L.C., Guo M.D., and Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 88 (2003) 5644-5649
122. Peacock M., Bilezikian J.P., Klassen P.S., Guo M.D., Turner S.A., and Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 90 (2005) 135-141
123. Ogata H., Ritz E., Odoni G., Amann K., and Orth S.R. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J. Am. Soc. Nephrol. 14 (2003) 959-967
124. Wada M., Furuya Y., Sakiyama J., Kobayashi N., Miyata S., Ishii H., and Nagano N. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. J. Clin. Invest. 100 (1997) 2977-2983
125. Roussanne M.C., Lieberherr M., Souberbielle J.C., Sarfati E., Drueke T., and Bourdeau A. Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate. Eur. J. Clin. Invest. 31 (2001) 610-616
126. Wada M., Ishii H., Furuya Y., Fox J., Nemeth E.F., and Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. 53 (1998) 448-453
127. Wada M., Nagano N., Furuya Y., Chin J., Nemeth E.F., and Fox J. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int. 57 (2000) 50-58
128. Fox J., Lowe S.H., Petty B.A., and Nemeth E.F. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J. Pharmacol. Exp. Ther. 290 (1999) 473-479
129. Silver J., Moallem E., Kilav R., Epstein E., Sela A., and Naveh-Many T. New insights into the regulation of parathyroid hormone synthesis and secretion in chronic renal failure. Nephrol. Dial. Transplant. 11 (1996) 2-5
130. Sudhaker Rao D., Han Z.H., Phillips E.R., Palnitkar S., and Parfitt A.M. Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesis. Clin. Endocrinol. (Oxf) 53 (2000) 373-381
131. Yano S., Sugimoto T., Tsukamoto T., Chihara K., Kobayashi A., Kitazawa S., Maeda S., and Kitazawa R. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. 58 (2000) 1980-1986
132. Block G.A., Martin K.J., de Francisco A.L., Turner S.A., Avram M.M., Suranyi M.G., Hercz G., Cunningham J., Abu-Alfa A.K., Messa P., Coyne D.W., Locatelli F., Cohen R.M., Evenepoel P., Moe S.M., Fournier A., Braun J., McCary L.C., Zani V.J., Olson K.A., Drueke T.B., and Goodman W.G. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350 (2004) 1516-1525
133. Antonsen J.E., Sherrard D.J., and Andress D.L. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int. 53 (1998) 223-227
134. Goodman W.G., Frazao J.M., Goodkin D.A., Turner S.A., Liu W., and Coburn J.W. A agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. 58 (2000) 436-445
135. Goodman W.G., Hladik G.A., Turner S.A., Blaisdell P.W., Goodkin D.A., Liu W., Barri Y.M., Cohen R.M., and Coburn J.W. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. 13 (2002) 1017-1024
136. Lindberg J.S., Moe S.M., Goodman W.G., Coburn J.W., Sprague S.M., Liu W., Blaisdell P.W., Brenner R.M., Turner S.A., and Martin K.J. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int. 63 (2003) 248-254
137. Ohashi N., Uematsu T., Nagashima S., Kanamaru M., Togawa A., Hishida A., Uchida E., Akizawa T., and Koshikawa S. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br. J. Clin. Pharmacol. 57 (2004) 726-734